Helen Davis

PMI U.S. touts its $35M in community giving. But can corporate generosity escape the shadow of the tobacco industry? A deep dive into a complex issue.

A new survey on luxury property reveals an overlooked trend: an influx of affluent, middle-aged buyers poised to reshape Greece's private healthcare market.

Warner Music Group's landmark deal with AI leader Suno settles a lawsuit and sets a new precedent for artist control and monetization in music's AI era.

Just two months after a splashy IPO, StubHub faces a class-action lawsuit over alleged misleading financial reports, sending its stock tumbling.

With impressive Phase 2 results showing significant weight loss and A1c reduction, Novo Nordisk's amycretin is poised to challenge market leaders.

Facing market headwinds, consultancy Next 15 is betting on a radical overhaul. We analyze its AI pivot, strategic disposals, and path to future growth.

Paratus AMC's early call on mortgage-backed notes sends ripples through structured finance, forcing investors to grapple with reinvestment risk.

A routine filing reveals Eutelsat's radical transformation. The satellite giant is betting its future on a hybrid orbit strategy to power the world.

Beyond the music, Zach Bryan's massive 2026 tour with AEG Presents reveals a powerful new blueprint for market dominance in live entertainment.

Pluxee's recent share repurchase is more than a financial footnote. It's a telling indicator of management's confidence in the booming corporate wellness market.

Bruker acquires AST Revolution, a firm born from bankruptcy just 3 months ago. This is a story of a swift PE exit and a major bet on fighting superbugs.

Turkish CPG giant ETİ Gıda acquires Canadian plant-based brand TRUBAR, a strategic move shaking up the North American better-for-you snack market.

Activist investor Engaged Capital demands records from BlackLine's board over a rejected $4.5B SAP offer, setting the stage for a major proxy battle.

After selling its first FDA-approved drug, Seres Therapeutics pivots to its next-gen candidate, SER-155, facing a make-or-break moment for its future.

Executive Chairman Gabriele Cerrone significantly increases his stake in OKYO Pharma as the biotech nears potential FDA breakthrough with Urcosimod for neuropathic corneal pain and dry eye. Is this a signal of confidence or a calculated risk?

With promising late-stage data anticipated in early 2026, Theravance Biopharma is actively engaging investors, highlighting its pipeline and improved financial footing. Focus is on a potential breakthrough for Multiple System Atrophy.

Updated MHRA GMP certification for Piramal Pharma Solutions' Grangemouth facility signals continued investment in UK biomanufacturing, crucial for the rapidly growing antibody-drug conjugate market. The move promises faster timelines for innovative cancer therapies.

Social media management platform Sprout Social unveils 'Sprout AI' featuring 'Trellis,' an AI agent designed to move beyond reactive monitoring and provide proactive insights for businesses.

With promising Phase 2 data and a diversified pipeline targeting hypoparathyroidism, obesity, and post-bariatric hypoglycemia, MBX Biosciences is positioning itself as a key player in the evolving metabolic disease landscape. Analysts predict significant growth potential.

With a new commercialization approach for APHEXDA and promising clinical programs in pancreatic and brain cancers, BioLineRx is navigating market shifts with a leaner operation and renewed focus on innovation.